Future research should focus on:1the heterogeneity in Dex responses among TLS cellular components (e.g., follicular dendritic cells, B cell subsets);2epigenetic regulatory differences in GR signaling pathways across breast cancer subtypes;3TLS maturity-based stratified therapeutic strategies. The gene discussed is NR3C1; the disease is breast carcinoma.